During our first decade, we focused our efforts on Over The Counter (OTC) medicines. Haben series have been one of our most successful products. As a medium-sized firm, it was not easy for us to become the leading company in this market. The key factors for this success were the superiority of the product itself as well as the implementation of proper marketing strategy. Our second decade can be represented by the passion to develop prescription medicine. Our business is applying the latest advances of technology to make innovative medicines for treating human illness. Our progress today was build upon our challenging past. We are passionate about what we do. We apply that passion to serve the needs of our patients, the medical profession, and our employees based on the continuing pursuit of excellent science. We never forget that our efforts benefit people like you. That knowledge motivates us every day. Our passion has brought us to where we are today. In 1997, we launched Lansoprazole(Second generation proton pump inhibitor --- Anti-peptic ulcer agent). We were the first company in Korea to have developed Lansoprazole by our own R&D effort. Looking forward to the future, we are focusing our efforts toward developing medicines in the areas of gastrointestinal medicine and oncology, while also remaining open to the opportunities in other areas of disease. The company's R&D investment is a major initiative that will continue to fuel KDC's steady and reliable growth. This investment will enable the company to remain a valuable contributor to both its brand and generic market. o keep our promise of the new millennium and forthcoming future, we will work harder than we ever have before. Thank you again for your visiting and commitment.   Sincerely Hai Ryong Park President & CEO Korean Drug Co.,Ltd